Lupin Limited today announced that its alliance partner Caplin Steriles Limited has received final approval from the United States Food and Drug Administration (U.S.FDA) for its Abbreviated New Drug Application (ANDA) Rocuronium Bromide Injection, via an exchange filing.
The approved dosages are 10mg/mL in 5 mL and 10 mL Multi-Dose Vials, to market a generic version of Zemuron Bromide Injection, 50 mg/5 mL and 100 mg/10 mL of Organon USA Inc.
Rocuronium Bromide Injection (RLD: Zemuron) had an annual sale of approximately USD 53 million in the U.S. (IQVIA MAT December 2022).
Read Also
Lupin’s alliance partner Caplin receives USFDA approval for Thiamine Hydrochloride Injection
Year-Ender 2025: Big Verdicts, Financial Crime Probes And High-Stakes Trials Mark Maharashtra’s Judicial Year
Sikkim State Lottery Result: December 29, 2025, 6 PM Live - Watch Streaming Of Winners List Of Dear Legend Monday Weekly Draw
Year-Ender 2025: BMC’s Administrator Era Sees Bridges, Coastal Road And Mega Projects Take Shape
Year-Ender 2025: Landmark Verdicts, Bail Orders And High-Profile Rulings That Shaped Bombay High Court’s Judicial Year
